US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback